Nausea drug may unlock new hypertension treatment in diabetes

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or menopausal female subjects; * Age ranging 18-30 years old; * Submitted to a social security regimen; * Agreeing to the study \& Informed consent form signed; * Body mass index (\[weight (kg)/height (m)\]²) \< 27; * No treatment received 6 weeks before inclusion; * No anomaly after: complete clinical examination, pulse and blood pressure measurement, ECG; * No biological abnormality after the following biological testing: Hematology: white \& red blood cells \& platelets count, haemoglobin, hematocrit, Blood biochemistry: sodium, potassium, chloride, bicarbonate, creatinine, urea, Urinary biochemistry (24 h collection): cortisol, aldosterone, Serologies: HIV, HBV, HCV, * No participation in a clinical trial 3 months ago before inclusion, * Subscription to national social security, * Signed informed consent. Exclusion Criteria: * Female subject potentially pregnant, * Subject younger than 18 year-old and older than 70 year-old, * Subject without diabetes condition or with diabetes but normal blood pressure (below 130/80 mmHg), * Subject with glycated hemoglobin HbA1c \< 6.5% or \>11%, * Subject with leuconeutropenia (neutrophils below 1700/mm3), * Subject with severe medical or surgical history, * Patients treated with drugs metabolized by CYP3A4 and CYP2C9: corticosteroids, vitamin K , hormonal contraceptives, tolbutamide, benzodiazepines, derived from ergot, antiepileptics, hypericum, macrolides, azole antifungals. * Patients treated with drugs interfering with the renin-angiotensin- aldosterone system : beta-blockers, diuretics , anti -aldosterone drugs , direct renin inhibitors , insulin, * type 2 diabetes patients with a vegetative autonomic neuropathy, * Patients with adrenal mass was diagnosed at imaging, * hepatic or renal impairment (defined respectively by secondary clinical and biological manifestations altered hepatocyte functions or estimated glomerular filtration rate less than 60 mL / min / 1.73 m2);nephrotic syndrome (defined by hypoalbuminemia less than 30 g / L associated with proteinuria at 3 grams / 24 hours);edematous syndrome (defined by the presence of edema of the lower limbs), * Orthostatic hypotension (defined by a decrease in systolic blood pressure of 20 mmHg and at least the diastolic blood pressure of 10 mmHg or more), * arrhythmias or cardiac conduction, * heart failure (NYHA class II minimum), * epilepsy, * serious psychiatric condition, * Severe allergic history, hypersensitivity to aprepitant, * People with hereditary problems of fructose intolerance, glucose malabsorption, galactose, or sucrase-isomaltase, * People with lactose intolerance, * subject unwilling or cannot be followed regularly. Persons deprived of their liberty by a judicial or administrative decision, those hospitalized without consent and those admitted to a health or social establishment for purposes other than research, the adults subject to a measure of legal protection or unable to consent may not be included.